Anti-mold Azole in the Prophylaxis for Invasive Fusariosis
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Patients admitted for autologous or allogeneic hematopoietic cell transplantation,
induction-remission chemotherapy for acute myeloid leukemia, myelodysplasia or acute lymphoid
leukemia, or to receive immunosuppressive therapy for aplastic anemia will be screened with
dermatologic examination. In the presence of any skin lesion in the extremities, direct exam
and fungal culture will be performed. If these exams indicate the presence of Fusarium
species, patients will receive anti-mold azole prophylaxis